RA0593

antibody from Oursmab

Targeting: CD274 B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0593

Provider

Oursmab

Product name

Atezolizumab (Biosimilar Reference Antibody) (PDL1)

Antibody type

Monoclonal

Description

Atezolizumab is a fully humanized, engineered monoclonal antibody of the IgG1 isotype, designed as an immune checkpoint inhibitor. It specifically targets programmed death-ligand 1 (PD-L1), blocking its interaction with the PD-1 and B7.1 (CD80) receptors on immune cells. This blockade releases inhibitory signals on T cells, thereby reinvigorating the anti-tumor immune response. Developed by Genentech/Roche, it is approved for the treatment of multiple advanced cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and urothelial carcinoma, often in combination with chemotherapy or other agents.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.